Back
Full-text
Journal article

Recent advances in intra-articular drug delivery systems for osteoarthritis therapy.

  • Maudens P School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, 1211 Geneva, Switzerland. Electronic address: pierre.maudens@unige.ch.
  • Jordan O School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, 1211 Geneva, Switzerland.
  • Allémann E School of Pharmaceutical Sciences, University of Geneva, University of Lausanne, 1211 Geneva, Switzerland.
  • 2018-05-25
Published in:
  • Drug discovery today. - 2018
Animals
Antirheumatic Agents
Delayed-Action Preparations
Drug Delivery Systems
Drug Design
Drug Development
Humans
Injections, Intra-Articular
Osteoarthritis
English Osteoarthritis (OA) is the most common degenerative disease of the joint. Despite many reports and numerous clinical trials, OA is not entirely understood, and there is no effective treatment available for this disease. To satisfy this unmet medical need, drug delivery systems (DDSs) containing disease-modifying OA drugs (DMOADs) for intra-articular (IA) administration are required to improve the health of OA patients. DDSs should provide controlled and/or sustained drug release, enabling long-term treatment with a reduced number of injections. This paper reviews the role and interaction among different tissues involved in OA and summarizes recent clinical trials and research on DDSs, focusing on small-molecule delivery. To achieve an ideal treatment, various key criteria have been identified to design and develop an IA DDS matching the clinical needs.
Language
  • English
Open access status
green
Identifiers
Persistent URL
https://sonar.ch/global/documents/116452
Statistics
Document views: 44 File downloads:
  • Full-text: 0